Learn About Paramyotonia Congenita

What is the definition of Paramyotonia Congenita?

Paramyotonia congenita is a disorder that affects muscles used for movement (skeletal muscles). Beginning in infancy or early childhood, people with this condition experience bouts of sustained muscle tensing (myotonia) that prevent muscles from relaxing normally. Myotonia causes muscle stiffness that typically appears after exercise and can be induced by muscle cooling. This stiffness chiefly affects muscles in the face, neck, arms, and hands, although it can also affect muscles used for breathing and muscles in the lower body. Unlike many other forms of myotonia, the muscle stiffness associated with paramyotonia congenita tends to worsen with repeated movements.

What are the causes of Paramyotonia Congenita?

Mutations in the SCN4A gene cause paramyotonia congenita. This gene provides instructions for making a protein that is critical for the normal function of skeletal muscle cells. For the body to move normally, skeletal muscles must tense (contract) and relax in a coordinated way. Muscle contractions are triggered by the flow of positively charged atoms (ions), including sodium, into skeletal muscle cells. The SCN4A protein forms channels that control the flow of sodium ions into these cells.

How prevalent is Paramyotonia Congenita?

Paramyotonia congenita is an uncommon disorder; it is estimated to affect fewer than 1 in 100,000 people.

Is Paramyotonia Congenita an inherited disorder?

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In many cases, an affected person has one parent with the condition.

Who are the top Paramyotonia Congenita Local Doctors?
Elite in Paramyotonia Congenita
Elite in Paramyotonia Congenita

Ambulatory Care Center

417 N. 11th Street, 
Richmond, VA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Nicholas Johnson is a Neurologist in Richmond, Virginia. Dr. Johnson is rated as an Elite provider by MediFind in the treatment of Paramyotonia Congenita. His top areas of expertise are Paramyotonia Congenita, Myotonic Dystrophy, Myotonic Dystrophy Type 2, and Limb-Girdle Muscular Dystrophy. Dr. Johnson is currently accepting new patients.

Elite in Paramyotonia Congenita
Elite in Paramyotonia Congenita
Milan, IT 

Giovanni Meola practices in Milan, Italy. Mr. Meola is rated as an Elite expert by MediFind in the treatment of Paramyotonia Congenita. His top areas of expertise are Myotonic Dystrophy, Myotonic Dystrophy Type 2, Paramyotonia Congenita, Amyotonia Congenita, and Thymectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Paramyotonia Congenita
Elite in Paramyotonia Congenita
6, Dr. Subotic Sr. Street, 11 000, 
Belgrade, SE, RS 

Stojan Peric practices in Belgrade, Serbia. Peric is rated as an Elite expert by MediFind in the treatment of Paramyotonia Congenita. Their top areas of expertise are Paramyotonia Congenita, Myotonic Dystrophy, Myotonic Dystrophy Type 2, and Myasthenia Gravis.

What are the latest Paramyotonia Congenita Clinical Trials?
National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family Members

Summary: Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are inherited disorders characterized by progressive muscle weakness and loss of muscle tissue. The purpose of this registry is to connect people with DM or FSHD with researchers studying these diseases. The registry will offer individuals with DM and FSHD an opportunity to participate in research that focuses of their disea...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/Phase 2 Open-label Single Arm Study With Dose Escalation (Part A), and Dose Expansion (Part B) Parts to Evaluate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants 10 to 50 Years Old With Non-congenital Myotonic Dystrophy Type 1

Summary: This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 50 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1). The purpose of this study is to evaluate the safety and efficacy of SAR446268 in knocking down dystrophia myotonica protein kinase (DMPK) messenger ribonucleic acid (mRNA) leve...

Who are the sources who wrote this article ?

Published Date: August 01, 2015
Published By: National Institutes of Health